SAN DIEGO--(BUSINESS WIRE)--Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today that it has been issued four patents by the U.S. Patent and Trademark Office for inventions related to diabetes and Alzheimers disease biomarkers. The current patents are the most recent in a series describing biomarkers associated with these diseases.
